Joshua Brumm

Josh brings extensive healthcare leadership experience to his role at Dyne. Previously, he served as a chief operating officer and chief financial officer of Kaleido Biosciences, where he led the company’s financings including its initial public offering, and helped bring the lead program into Phase 2 development. Prior to joining Kaleido, Josh was COO and CFO at Versartis, where he spearheaded the company’s financial strategy including the successful completion of its IPO, played an integral role in product strategy, and helped negotiate the company’s first product partnership. His previous roles include serving as executive vice president of finance and principal financial officer at Pharmacyclics; CFO at ZELTIQ Aesthetics, where he led the company through its initial public offering, led the international product launch for CoolSculpting and also served in corporate development; and director of finance at Proteolix, Inc., assisting in the sale of the company to Onyx Pharmaceuticals. He also held investment banking positions at Citigroup Global Markets, Inc. and Morgan Stanley. Over the course of his career, Josh has raised nearly $2 billion in the capital. Josh serves as Chairman of the Board of Amphista Therapeutics, a company focused on advancing targeted protein degradation therapeutics. He holds a B.A. in business administration from the University of Notre Dame.